Moleac Pte Ltd.   Report issue

For profit Phase 3 Phase 4
Founded: Singapore Singapore (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2008
NCT00721825
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Moleac Australia Pty Ltd | Moleac Pte Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

neuroaid (2 trials)

Drugs in Phase 3 Trials (2)

astragalus membranaceus (1 trial)

mlc1501 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 2)

Hypersensitivity (Phase 1)

Infarction (Phase 2)

Spinal Cord Injuries (Phase 4)

Stroke (Phase 2)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 3